After confirming an increase in AR activity in CR-T24 cells, we utilized the KDM7A inhibitor TC-E 5002, in conjunction with AR antagonist enzalutamide, to evaluate the role of KDM7A on bladder cancer growth and drug resistance in terms of the AR pathway. The gene discussed is KDM7A; the disease is urinary bladder cancer.